Relevance of new psychotropic drugs for the neurologist

Journal of Neurology Neurosurgery and Psychiatry

Volumn 72, Issue 3, 2002, Pages 281-285

  Hensiek, A E ^a   Trimble, M R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; CITALOPRAM; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE RECEPTOR; FLUOXETINE; HALOPERIDOL; HISTAMINE H2 RECEPTOR; IMIPRAMINE; MIRTAZAPINE; MUSCARINIC RECEPTOR; NEFAZODONE; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; QUETIAPINE; REBOXETINE; RISPERIDONE; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SERTRALINE; VENLAFAXINE;

AVOIDANCE BEHAVIOR; CATALEPSY; DRUG RECEPTOR BINDING; EDITORIAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL;

EID: 0036191870     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.72.3.281     Document Type: Editorial

References (67)

1. Dopamine receptors and antipsychotic drug response
2. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia
3. Clozapine for the treatment-resistant schizophrenia. A double-blind comparison with chlorpromazine
4. Atypical neuroleptics
5. Clozapine for the treatment of psychosis in Parkinson's disease: A review
6. Clozapine-related seizures
7. What makes an antipsychotic atypical
8. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine
9. Atypical neuroleptics: Role of multiple receptors, endogenous dopamine, and receptor linkage
10. Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development
11. Neurochemical characteristics of amisulpiride, an atypical D2/D3 receptor antagonist with both presynaptic and limbic selectivity
12. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
13. Receptor pharmacology of neuroleptics: Relation to clinical effects
14. Dopamine D4 receptors are elevated in schizophrenia
15. Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia
16. New antipsychotics
17. The effects of clozaopine on tardive dyskinesia
18. Neurologic side effects in neuroleptic naïve patients treated with haloperidol or risperidone
19. Atypical neuroleptics in movement disorders
20. Quetiapine (Seroquel); an effective and well-tolerated atypical antipsychotic
21. Dopaminergic psychosis in Parkinson's disease patients: Diagnosis and treatment
22. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease
23. Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentred clinical experience
24. Low dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease
25. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes
26. Worsening of motor features of parkinsonism with olanzapine
27. Olanzapine in the treatment of dopaminergic psychosis in patients with Parkinson's disease
28. Efficacy of quetiapine in Parkinson's patients with psychosis
29. Quetiapine for the treatment of drug induced psychosis in Parkinson's disease
30. Epidemiology of depression
31. Depression in epilepsy: Etiology, phenomenology and treatment
32. Noradrenergic versus serotinergic antidepressants: Predictors of treatment response
33. The neuroanatomy of depression
34. Antidepressants and convulsive seizures: Clinical, electroencephalographic and pharmacologic aspects
35. Non-monoamine oxidase inhibitor antidepressants and epilepsy: A review
36. Treatment of severe depression with imipramine: An investigation of 100 cases
37. Antidepressants and convulsions
38. Seizures associated with antidepressants. A review
39. Psychotropic drug-induced seizures
40. Not so selective serotonin re-uptake inhibitors
41. Citalopram: A review of its pharmacology, clinical efficacy and tolerability in the treatment of depression
42. Selecting an antidepressant for use in a patient with epilepsy. Safety considerations
43. Selective serotonin re-uptake inhibitors: An update
44. Movement disorders associated with the serotonin re-uptake inhibitors
45. Mechanism of action of antidepressant medications
46. Chairman's overview. The place of reboxetine in antidepressant therapy
47. Reboxetine: Additional beliefs to the depressed patients
48. Venlafaxine
49. The clinical effectiveness of venlafaxine in the treatment of depression
50. Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action
51. The adverse effects of antidepressants
52. The pharmacological profile of mirtazepine
53. Pharmacology of antidepressants: Selectivity or multiplicity?
54. Safety of mirtazepine: A review
55. A double blind comparison of Org 3770, amitryptiline and placebo in major depression
56. Mirtazepine is more effective than trazodone: A double blind controlled study on hospitalised patients with major depression
57. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites
58. Effect of paroxetine on seizure length during electroconvulsive therapy
59. The safety profile of paroxetine
60. Seizure and transient SIADH associated with sertraline
61. Sertraline overdose
62. Il trattamento antidepressivo con citalopram in pazienti con epilessia: Dati preliminari
63. Citalopram overdose. Review of cases treated in Swedish hospitals
64. Seizure resulting from a venlafaxine overdose
65. The pharmacologic profile of paroxetine, a new selective serotonin re-uptake inhibitor
66. Psychopharmacological profile of the selective serotonin re-uptake inhibitor paroxetine: Implication of noradrenergic and serotinergic mechanisms
67. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obscessive-compulsice disorder